SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2024 financial results on Thursday, March 20, 2025. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.
Initial bioassay data for Cibus' third mode of action for white mold (Sclerotinia) resistance trait in canola shows promising results in controlled environment assessment
SAN DIEGO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced key leadership changes pursuant to the Company's succession planning strategy. The Board has accepted Rory Riggs' resignation as the Company's Chief Executive Officer. Peter Beetham, the Company's President and Chief Operating Officer, also will serve as the Company's Interim Chief Executive Officer. Dr. Beetham is a co-founder of Cibus Global with Mr. Riggs and with Greg Gocal, who will remain the Company's Chief Scientific Officer. Mr. Riggs will remain Chairman of the Board of Directors. Dr. Beetham also will continue as a director.
SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced it has entered into securities purchase agreements with existing investors of the Company, including institutional and strategic investors, as well as with the Company's CEO, Rory Riggs, for the purchase and sale of 9,040,000 shares of its Class A Common Stock (inclusive of pre-funded warrants to purchase shares of Class A Common Stock, in lieu of common stock), and warrants to purchase up to an aggregate of 9,040,000 shares of Class A Common Stock, at a combined purchase price per share (and accompanying warrant) of $2.50 per share ($2.4999 in respect of the pre-funded warrants (and accompanying warrant)), pursuant to a registered direct offering priced above Nasdaq's Minimum Price in accordance with Nasdaq rules. The warrants will be exercisable upon stockholder approval at a price of $2.50 per share, and will expire five years following the date of stockholder approval. Following stockholder approval, the warrants will be redeemable, at the Company's option, at a redemption price of $0.0001 per warrant following the satisfaction of certain conditions, including (i) the Company's announcement of an operational soybean platform and (ii) the closing price of the Class A Common Stock equaling or exceeding $5.00 per share for fifteen consecutive trading days.
Cibus and Biographica to collaborate on identifying gene editing targets for Cibus' disease resistance trait development
Cibus, Inc. (NASDAQ:CBUS ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Carlo Broos - Chief Financial Officer Rory Riggs - Co-Founder, Chairman and CEO Peter Beetham - Co-Founder, President and COO Conference Call Participants Laurence Alexander - Jefferies Austin Moeller - Canaccord Matthew Venezia - Alliance Global Partners Operator Good day, and welcome to the Cibus Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
The greenhouse results represent an important success milestone in the development of its second-generation of HT2 edited Canola
SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report third quarter 2024 financial results on Thursday, November 7, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.
Projected Cost Savings of Approximately $10 Million on Annualized Run-Rate Basis and Expected to Reduce Cash Use by Approximately 20% Projected Cost Savings of Approximately $10 Million on Annualized Run-Rate Basis and Expected to Reduce Cash Use by Approximately 20%
SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, has been named a finalist for the Euroseeds2024 InnovActor Award and will have its technology showcased on the InnovAction Stage at the Euroseeds2024 Congress. Cibus' presentation will be given by Dr. Jim Radtke (SVP Product Development) who was recently honored by the American Seed Trade Association (ASTA) with a Lifetime Achievement Award. The event will take place in Copenhagen, Denmark, October 13-16 with the winner named at the 2024 InnovActor Ceremony on October 15.